Peter McCullough, MD, observes various eye conditions post-COVID-19 vaccination, linking spike protein to bleeding and clotting issues. Ocular hemorrhage reports highlight risk factors like diabetes; however, no evidence shows blood thinners contributing to these events. McCullough maintains that risks of clotting outweigh bleeding risk and continues to recommend anticoagulants while advising patients on bleeding dangers.
Ocular Hemorrhage Attributed to COVID-19 Vaccination Risk Factors Include Diabetes, Prior Eye Surgery, and Ocular Injections but Not Oral Anticoagulants Thu, 22 Aug 2024 10:12:19 GMT https://petermcculloughmd.substack.com/p/ocular-hemorrhage-attributed-to-covid By Peter A. McCullough, MD, MPH
In clinical practice I have seen a range of ocular pathologies in patients after COVID-19 vaccination and confirmed findings with ophthalmologists. One thing I have learned is that the Spike protein from COVID-19 vaccination can cause a wide array of both bleeding and clotting abnormalities long after injection. This may be worsened by intercurrent COVID-19 illness. Because of the widespread use of fibrinolytic and anticoagulant supplements (nattokinase, bromelain) and medicinal antiplatelet and anticoagulant drugs (aspirin, clopidogrel, apixaban, rivaroxaban, dabigatran, warfarin), I wondered if use of these agents was worsening the risk of bleeding in the eye among the vaccinated.
I found numerous reports of ocular hemorrhage after COVID-19 vaccination. Diabetes, prior cataract surgery, and injections for macular degeneration were cited as risk factors or co-incident conditions. It was interesting that not a single report cited an over-the-counter or prescription blood thinner as a contributing factor.
While all supplements and drugs have risks and benefits, I believe our usual and customary practice of warning patients concerning mucosal and major bleeding is reasonable. The risks of clotting after vaccination far outweigh the risks of bleeding, and thus will continue to recommend anticoagulant regimens in the appropriate clinical scenarios with bleeding caveats given to patients.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Park HS, Byun Y, Byeon SH, Kim SS, Kim YJ, Lee CS. Retinal Hemorrhage after SARS-CoV-2 Vaccination. J Clin Med. 2021 Dec 5;10(23):5705. doi: 10.3390/jcm10235705. PMID: 34884407; PMCID: PMC8658415.
Matsuo T, Noda H. Temporal association of vitreous hemorrhage and hypertension after COVID-19 mRNA vaccines. Clin Case Rep. 2022 Nov 27;10(11):e6657. doi: 10.1002/ccr3.6657. PMID: 36447668; PMCID: PMC9702347.
Abu Serhan H, Abdelaal A, Abuawwad MT, Taha MJJ, Irshaidat S, Abu Serhan L, Abu-Ismail L, Abu Salim QF, Abdelazeem B, Elnahry AG. Ocular Vascular Events following COVID-19 Vaccines: A Systematic Review. Vaccines. 2022; 10(12):2143. https://doi.org/10.3390/vaccines10122143
Choi, M.; Seo, M.-H.; Choi, K.-E.; Lee, S.; Choi, B.; Yun, C.; Kim, S.-W.; Kim, Y.Y. Vision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019. J. Clin. Med. 2022, 11, 3318. https://doi.org/10.3390/ jcm11123318
Tsuda K, Oishi A, Kitaoka T. Optic disc hemorrhage in a young female following mRNA coronavirus disease 2019 vaccination: a case report. J Med Case Rep. 2022 Dec 8;16(1):462. doi: 10.1186/s13256-022-03690-3. PMID: 36482489; PMCID: PMC9733278.
Ng XL, Betzler BK, Testi I, Ho SL, Tien M, Ngo WK, Zierhut M, Chee SP, Gupta V, Pavesio CE, de Smet MD, Agrawal R. Ocular Adverse Events After COVID-19 Vaccination. Ocul Immunol Inflamm. 2021 Aug 18;29(6):1216-1224. doi: 10.1080/09273948.2021.1976221. Epub 2021 Sep 24. PMID: 34559576; PMCID: PMC8477588.
Furukawa A, Suzuki Y, Nozuki N, Kurosaka N, Kogawa S, Hara S, Ueno S. Case report: A case of unilateral combined central retinal vein occlusion, incomplete central retinal artery occlusion, and papillitis following a third dose of COVID-19 vaccination. Front Ophthalmol (Lausanne). 2024 Feb 23;4:1352962. doi: 10.3389/fopht.2024.1352962. PMID: 38984132; PMCID: PMC11182238.